Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Royalty Pharma PLC (RPRX)
NASDAQ:RPRX
Holding RPRX?
Track your performance easily
RPRX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$25.10 - $31.66
Previous Close$26.01
Volume3.13M
Average Volume (3M)2.46M
Market Cap
$15.33B
Enterprise Value$25.32B
Total Cash (Recent Filing)$998.55M
Total Debt (Recent Filing)$7.61B
Price to Earnings (P/E)10.2
Beta0.58
Next Earnings
Feb 12, 2025EPS Estimate
$0.99Last Dividend Ex-Date
Nov 15, 2024Dividend Yield3.24%
Share Statistics
EPS (TTM)2.56
Shares Outstanding589,182,783
10 Day Avg. Volume2,592,990
30 Day Avg. Volume2,461,845
Standard Deviation0.06
R-Squared0.13
Alpha-0.01
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)2.19
Price to Sales (P/S)6.76
Price to Cash Flow (P/CF)5.40
P/FCF Ratio5.40
Enterprise Value/Market CapN/A
Enterprise Value/Revenue11.18
Enterprise Value/Gross Profit10.76
Enterprise Value/Ebitda14.16
Forecast
1Y Price Target
$44.00Price Target Upside71.94% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Royalty Pharma News
PremiumCompany Announcements
Royalty Pharma Reports Strong Q3 2024 Results
Ownership Overview
8.05% Insiders
17.77% Mutual Funds
20.50% Other Institutional Investors
35.78% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
RPRX FAQ
What was Royalty Pharma PLC’s price range in the past 12 months?
Royalty Pharma PLC lowest stock price was $25.10 and its highest was $31.66 in the past 12 months.
What is Royalty Pharma PLC’s market cap?
Currently, no data Available
When is Royalty Pharma PLC’s upcoming earnings report date?
Royalty Pharma PLC’s upcoming earnings report date is Feb 12, 2025 which is in 50 days.
How were Royalty Pharma PLC’s earnings last quarter?
Royalty Pharma PLC released its earnings results on Nov 06, 2024. The company reported $0.917 earnings per share for the quarter, missing the consensus estimate of $0.927 by -$0.01.
Is Royalty Pharma PLC overvalued?
According to Wall Street analysts Royalty Pharma PLC’s price is currently Undervalued.
Does Royalty Pharma PLC pay dividends?
Royalty Pharma PLC pays a Quarterly dividend of $0.209 which represents an annual dividend yield of 3.24%. See more information on Royalty Pharma PLC dividends here
What is Royalty Pharma PLC’s EPS estimate?
Royalty Pharma PLC’s EPS estimate is $0.99.
How many shares outstanding does Royalty Pharma PLC have?
Royalty Pharma PLC has 444,301,670 shares outstanding.
What happened to Royalty Pharma PLC’s price movement after its last earnings report?
Royalty Pharma PLC reported an EPS of $0.917 in its last earnings report, missing expectations of $0.927. Following the earnings report the stock price went down -3.259%.
Which hedge fund is a major shareholder of Royalty Pharma PLC?
Among the largest hedge funds holding Royalty Pharma PLC’s share is Viking Global Investors LP. It holds Royalty Pharma PLC’s shares valued at 342M.
---
Royalty Pharma Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$44.00 (71.94% Upside)
$44.00 (71.94% Upside)
Blogger Sentiment
Bullish
RPRX Sentiment 85%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 493.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▼ 1.3%
Last 30 Days ▲ 1.3%
Last 30 Days ▲ 1.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-6.13%
12-Months-Change
Fundamentals
Return on Equity
17.62%
Trailing 12-Months
Asset Growth
13.79%
Trailing 12-Months
Company Description
Royalty Pharma PLC
New York-based Royalty Pharma Plc is a biopharmaceutical company, which is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry.
---
RPRX Company Deck
---
RPRX Earnings Call
Q3 2024
0:00 / 0:00
---
RPRX Revenue Breakdown
93.34% Income from financial royalty assets
6.62% Other royalty income
0.04% Revenue from intangible royalty assets
---
RPRX Stock 12 Month Forecast
Average Price Target
$44.00
▲(71.94% Upside)
Technical Analysis
Best Analysts Covering RPRX
1 Year
1 Year Success Rate
2/17 ratings generated profit
1 Year Average Return
-11.39%
reiterated a buy rating 2 months ago
Copying Terence Flynn's trades and holding each position for 1 Year would result in 11.76% of your transactions generating a profit, with an average return of -11.39% per trade.
---